The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents
Por:
Atenza, CZ, Anguera, G, Melia, MR, De Lamo, LA, Sullivan, I, Joaquin, AB, Lopez, JS, Ortiz, MA, Mulet, M, Vidal, S, Majem, M
Publicada:
1 ago 2022
Ahead of Print:
1 ene 2022
Resumen:
Background Tumor PD-L1 expression is a predictive biomarker for patients with NSCLC receiving PD-(L)1 blockade agents. However, although increased tumor PD-L1 expression predicts responsiveness, clinical benefit has been observed regardless of tumor PD-L1 expression, suggesting the existence of other PD-L1 sources. The aim of our study was to analyze whether integrating systemic and tumor PD-L1 is more predictive of efficacy in patients with advanced NSCLC receiving PD-(L)1 blockade agents. Material and methods Twenty-nine healthy donors and 119 consecutive patients with advanced NSCLC treated with PD-(L)1 drug were prospectively included. Pretreatment blood samples were collected to evaluate PD-L1 levels on circulating immune cells, platelets (PLTs), platelet microparticles (PMPs), and the plasma soluble PD-L1 concentration (sPD-L1). Tumor PD-L1 status was assessed by immunohistochemistry. The percentages of circulating PD-L1 + leukocytes, sPD-L1 levels, and tumor PD-L1 were correlated with efficacy. Results No differences in the percentages of circulating PD-L1 + leukocytes were observed according to tumor PD-L1 expression. Significantly longer progression-free survival was observed in patients with higher percentages of PD-L1 + CD14 + , PD-L1 + neutrophils, PD-L1 + PLTs, and PD-L1 + PMPs and significantly longer overall survival was observed in patients with higher percentages of PD-L1 + CD14 + and high tumor PD-L1 expression. Integrating the PD-L1 data of circulating and tumor PD-L1 results significantly stratified patients according to the efficacy of PD-(L1) blockade agents. Conclusions Our results suggest that integrating circulating PD-L1 + leukocytes, PLT, PMPs, and sPD-L1 and tumor PD-L1 expression may be helpful to decide on the best treatment strategy in patients with advanced NSCLC who are candidates for PD-(L)1 blockade agents.
Filiaciones:
Atenza, CZ:
Biomed Res Inst St Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Anguera, G:
Hosp La Santa Creu & San Pau C, Dept Med Oncol, St Antoni Maria Claret 167, Barcelona 08025, Spain
Univ Autonoma Barcelona UAB, Dept Med, Barcelona, Spain
Melia, MR:
Hosp La Santa Creu & San Pau C, Dept Med Oncol, St Antoni Maria Claret 167, Barcelona 08025, Spain
Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
De Lamo, LA:
Hosp La Santa Creu & St Pau, Dept Immunol, Barcelona, Spain
Sullivan, I:
Hosp La Santa Creu & San Pau C, Dept Med Oncol, St Antoni Maria Claret 167, Barcelona 08025, Spain
Joaquin, AB:
Hosp La Santa Creu & San Pau C, Dept Med Oncol, St Antoni Maria Claret 167, Barcelona 08025, Spain
Lopez, JS:
Hosp La Santa Creu & San Pau C, Dept Med Oncol, St Antoni Maria Claret 167, Barcelona 08025, Spain
Ortiz, MA:
Biomed Res Inst St Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Mulet, M:
Biomed Res Inst St Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Vidal, S:
Biomed Res Inst St Pau IIB St Pau, Grp Immunol Inflammatory Dis, Barcelona, Spain
Majem, M:
Hosp La Santa Creu & San Pau C, Dept Med Oncol, St Antoni Maria Claret 167, Barcelona 08025, Spain
|